Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENGNNASDAQ:FHTXNASDAQ:LFCRNASDAQ:TNYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENGNenGene$4.30-9.5%$5.96$4.20▼$17.54$219.20M-0.61131,097 shs33,677 shsFHTXFoghorn Therapeutics$3.52-9.3%$4.62$3.52▼$10.25$195.75M3.13133,363 shs78,489 shsLFCRLifecore Biomedical$6.85+0.3%$6.14$3.68▼$7.99$253.62M0.96216,016 shs239,063 shsTNYATenaya Therapeutics$0.64-7.1%$0.90$0.39▼$5.25$56.26M2.832.14 million shs1.58 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENGNenGene-9.47%-13.31%-22.38%-33.02%-75.06%FHTXFoghorn Therapeutics-9.28%-13.09%-29.74%-26.97%-43.95%LFCRLifecore Biomedical+0.29%+4.58%+14.74%-5.91%+32.50%TNYATenaya Therapeutics-7.14%+0.91%-36.40%-57.17%-87.55%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENGNenGene3.2012 of 5 stars3.55.00.00.01.92.50.6FHTXFoghorn Therapeutics2.6241 of 5 stars3.53.00.00.02.71.70.6LFCRLifecore Biomedical1.4981 of 5 stars2.20.00.00.02.25.00.6TNYATenaya Therapeutics4.1006 of 5 stars3.54.00.00.03.35.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENGNenGene 3.00Buy$25.22486.56% UpsideFHTXFoghorn Therapeutics 3.00Buy$13.17274.05% UpsideLFCRLifecore Biomedical 2.33Hold$8.0016.79% UpsideTNYATenaya Therapeutics 3.00Buy$6.25872.91% UpsideCurrent Analyst Ratings BreakdownLatest TNYA, LFCR, ENGN, and FHTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2025TNYATenaya TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $6.003/12/2025TNYATenaya TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $5.003/12/2025TNYATenaya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $9.003/11/2025ENGNenGeneMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$37.00 ➝ $34.003/11/2025ENGNenGeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/11/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $5.003/7/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.002/18/2025ENGNenGenePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$26.002/14/2025ENGNenGeneUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$34.00 ➝ $7.002/3/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.001/30/2025FHTXFoghorn TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 3/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENGNenGeneN/AN/AN/AN/A$6.17 per shareN/AFHTXFoghorn Therapeutics$22.60M8.66N/AN/A($1.83) per share-1.92LFCRLifecore Biomedical$130.86M1.94N/AN/A$0.37 per share18.51TNYATenaya TherapeuticsN/AN/AN/AN/A$2.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENGNenGene-$55.14M-$1.52N/AN/AN/AN/A-16.69%-14.27%N/AFHTXFoghorn Therapeutics-$98.43M-$1.65N/AN/AN/A-357.53%N/A-30.98%5/5/2025 (Estimated)LFCRLifecore Biomedical$12.01M-$0.56N/AN/AN/A-12.52%-315.23%-12.74%4/3/2025 (Estimated)TNYATenaya Therapeutics-$124.08M-$1.32N/AN/AN/AN/A-86.17%-71.14%5/13/2025 (Estimated)Latest TNYA, LFCR, ENGN, and FHTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/3/2025N/ALFCRLifecore Biomedical-$0.14N/AN/AN/A$33.23 millionN/A3/17/2025Q4 2024TNYATenaya Therapeutics-$0.32-$0.28+$0.04-$0.28N/AN/A3/6/2025Q4 2024FHTXFoghorn Therapeutics-$0.43-$0.30+$0.13-$0.30$8.56 million$2.86 million1/2/2025Q2 2025LFCRLifecore Biomedical-$0.27-$0.25+$0.02-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENGNenGene$1.5836.77%N/AN/A N/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENGNenGene0.0816.8716.87FHTXFoghorn TherapeuticsN/A4.774.77LFCRLifecore Biomedical9.212.321.21TNYATenaya TherapeuticsN/A5.275.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENGNenGene64.16%FHTXFoghorn Therapeutics61.55%LFCRLifecore Biomedical83.36%TNYATenaya Therapeutics90.54%Insider OwnershipCompanyInsider OwnershipENGNenGene13.70%FHTXFoghorn Therapeutics9.07%LFCRLifecore Biomedical32.20%TNYATenaya Therapeutics32.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENGNenGene3150.98 million38.16 millionN/AFHTXFoghorn Therapeutics12055.61 million50.57 millionOptionableLFCRLifecore Biomedical69037.03 million26.58 millionOptionableTNYATenaya Therapeutics11087.58 million53.27 millionOptionableTNYA, LFCR, ENGN, and FHTX HeadlinesRecent News About These CompaniesChardan Capital Issues Optimistic Estimate for TNYA EarningsMarch 29 at 2:07 AM | americanbankingnews.comSA Asks: Which small/mid-cap cardiology stocks are undervalued?March 28 at 11:37 PM | msn.comIs Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?March 28 at 11:58 AM | insidermonkey.comWhat is Chardan Capital's Forecast for TNYA FY2025 Earnings?March 28 at 6:15 AM | marketbeat.comTenaya Therapeutics Publishes Positive Preclinical Data for TN-201 Gene Therapy Targeting MYBPC3-Associated Hypertrophic CardiomyopathyMarch 26 at 4:41 AM | nasdaq.comTenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in MarchMarch 25, 2025 | insidermonkey.comTop 3 Insider Stock Buys in March—Are They Still Good in April? (TNYA)March 25, 2025 | insidertrades.comTenaya Therapeutics publishes preclinical data on TN-201 in cardiac functionMarch 24, 2025 | markets.businessinsider.comTenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happyMarch 24, 2025 | finance.yahoo.comTenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy ModelsMarch 24, 2025 | globenewswire.comTenaya Therapeutics files $300M mixed securities shelfMarch 22, 2025 | markets.businessinsider.comTenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific SessionMarch 19, 2025 | markets.businessinsider.comTenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific SessionMarch 19, 2025 | globenewswire.comTenaya Therapeutics (NASDAQ:TNYA) Given New $6.00 Price Target at Canaccord Genuity GroupMarch 14, 2025 | marketbeat.comTenaya Therapeutics price target lowered to $6 from $18 at CanaccordMarch 13, 2025 | markets.businessinsider.comMorgan Stanley Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)March 12, 2025 | markets.businessinsider.comTenaya Therapeutics price target lowered to $5 from $15 at Morgan StanleyMarch 12, 2025 | markets.businessinsider.comTenaya Therapeutics price target lowered to $5 from $18 at H.C. WainwrightMarch 12, 2025 | markets.businessinsider.comTenaya Therapeutics price target lowered to $9 from $18 at ChardanMarch 12, 2025 | markets.businessinsider.comTenaya Therapeutics Advances Gene Therapy PipelineMarch 12, 2025 | tipranks.comInsiders Are Loading Up on These 4 Biotech Stocks NowMarch 11, 2025 | 247wallst.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNYA, LFCR, ENGN, and FHTX Company DescriptionsenGene NASDAQ:ENGN$4.30 -0.45 (-9.47%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$4.30 +0.00 (+0.12%) As of 03/28/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Foghorn Therapeutics NASDAQ:FHTX$3.52 -0.36 (-9.28%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$3.52 0.00 (0.00%) As of 03/28/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Lifecore Biomedical NASDAQ:LFCR$6.85 +0.02 (+0.29%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$6.85 0.00 (0.00%) As of 03/28/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Tenaya Therapeutics NASDAQ:TNYA$0.64 -0.05 (-7.14%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.64 +0.00 (+0.09%) As of 03/28/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
